QFINITY · News · Insights & Events
Shaping the regulated quality of tomorrow.
Articles and analysis from our own work across GxP, pharma, quality management, GAMP and AI - what is changing in the regulated environment, what it means in practice, and what is happening inside our company.
Latest articles
Nomination for the Roger F. Sherwood Award
We are very pleased that a QFINITY article has been nominated as a finalist for the 2024 Roger F. Sherwood Award.
The article is titled “Quality Considerations in Disaster Recovery: A Case Study.”
It was published in the January/February 2024 issue of the renowned journal Pharmaceutical Engineering. The article stands out for its thorough treatment of quality considerations in disaster recovery and has resonated strongly with readers. With this nomination, the ISPE (International Society for Pharmaceutical Engineering) recognizes the article’s quality and its relevance to the pharmaceutical industry.
The Roger F. Sherwood Award has been presented annually since 1993 and honors the best technical contributions published in Pharmaceutical Engineering. The award aims to highlight outstanding content, promote knowledge sharing within the industry, and underscore ISPE’s role as a global knowledge leader.
The winning article will be announced during the ISPE Annual Meeting & Expo 2025, taking place on 28 October in Charlotte, North Carolina.
At QFINITY, we are proud of this nomination and sincerely thank ISPE for recognizing our work. It motivates us to keep sharing our expertise with the industry.
You can find more information about the award on the ISPE website.
Explore more publications from QFINITY.
Read the article at Pharmaceutical Engineering (ispe.org)↗
ACDM AI Conference Report
At the two-day ACDM AI symposium 2025 in Frankfurt, QFINITY – through COO Marcus Schwabedissen, a standing steering-committee member – again contributed expertise on the validation, compliance, and ethics of AI-enabled systems and led the corresponding track.
In his opening remarks, Ashley Howard reflects on the first ACDM AI Symposium held in London. The photo features, among others, Oliver Herrmann (CEO, QFINITY) taking part in the major panel discussion of 2022.Following the success of the ACDM AI Conferences over the past three years and the rapid pace of development in Artificial Intelligence, ACDM once again hosted a two-day AI Conference in June 2025.
The AI Conference offered a diverse program including innovative training sessions, hands-on case studies, engaging presentations, expert panels, and numerous networking opportunities. The aim was to further the responsible use of AI technologies in clinical trials. Representatives from pharmaceutical companies, CROs, and technology providers gathered in Frankfurt to discuss current developments and future directions in Artificial Intelligence.
QFINITY once again supported the event through Marcus Schwabedissen, COO and a permanent Steering Committee member since 2022, who helped plan, prepare, and run it. He chaired the track on validation, compliance, and ethics in AI.
Given the positive feedback, ACDM looks forward to more successful AI Symposia in the future.
For more information about ACDM events, please click here.
QFINITY on the Steering Committee of the 4th ACDM AI Symposium
We are very pleased that QFINITY Qualitätsmanagement was represented on the Steering Committee of the 4th Annual Symposium on Artificial Intelligence in Clinical Trials hosted by the ACDM (Association for Clinical Data Management).
Our colleague Marcus Schwabedissen helped shape the program for this major industry event, together with five fellow experts from leading companies:
– Ashley Howard, Pfizer
– Tim Armitage, Medidata Solutions
– Marcus Schwabedissen, QFINITY Qualitätsmanagement
– Rob Nichols, Coronado Research
– Richard Davies, CluePoints
– Robert King, Thermo Fisher Scientific
The Steering Committee curated a strong, forward-looking program with great dedication and expertise, bringing together leading minds from industry, research, and technology to discuss the current state and future of artificial intelligence in clinical trials.
We thank the ACDM for its trust and for the opportunity to play an active part in shaping the symposium – and we look forward to more initiatives around AI and clinical data management.